Cellectar Biosciences Announces Partnership With BBK Worldwide

Cellectar Biosciences Announces Partnership With BBK Worldwide

Posted by Elizabeth Gargill on Thu, Oct 28, 2021



Earlier this week, Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, announced its partnership with BBK to provide concierge services for patients participating in its clinical studies. The services are designed to improve patients' and their caregivers' access to high-quality care and innovative treatments for their cancer.

“Cellectar’s new concierge services program underscores our focus on patients and our commitment to providing them with best-in-class treatments and support. Providing something as simple as securing transportation to clinics and lodging to assistance with reimbursement and study-related expenses can have a major positive impact on patients during very difficult times," said James Caruso, president and CEO of Cellectar. 

“We are thrilled to partner with Cellectar in support of patients that may benefit from treatment with iopofosine,” said Rob Laurens, principal and chief innovation officer of BBK Worldwide. “BBK is founded on the principle of putting the patient first, and we share Cellectar’s commitment to helping patients navigate the many challenges associated with cancer treatment.”

Read Full Press Release


Topics: Most Viewed, Concierge Services, Cellectar